Literature DB >> 15117123

Age-specific seroprevalence of hepatitis A infection among children visited in pediatric hospitals of Tehran, Iran.

Ali Jafari Mehr1, Mohammad Javad Ehsani Ardakani, Mehdi Hedayati, Saeed Shahraz, Elnaz Jafari Mehr, Mohammad Reza Zali.   

Abstract

BACKGROUND: Hepatitis A is an enterically transmitted disease that still remains endemic in many developing countries. In some countries improvements in living conditions have recently led to changing in epidemiology of hepatitis A virus (HAV) infection. In our country there are very few reports on prevalence of HAV infection.
OBJECTIVE: To determine the seroprevalence of anti-HAV IgG among children visited in pediatric hospitals of Tehran, Iran.
METHODS: The study group included 1018 children who were 6 months-14.9 years of age. These children were visited in four major pediatric hospitals of Tehran. The children were separated to three age groups: Group 1 (6 months-4.9 years; n = 469), Group 2 (5.0-9.9 years; n = 290), and Group 3 (10.0-14.9 years; n = 259). Serum anti-HAV IgG was tested with commercial ELISA kits. The data were tested for statistical significance with chi2 test.
RESULTS: In all subjects, seroprevalence of hepatitis A was 22.3% (95% CI: 19.7, 24.9). There was no significant difference between genders (22.2% vs. 22.5% in males and females, respectively) and among age groups (Group I was 22.1% and Group 3 was 25.9; p > 0.05).
CONCLUSIONS: In summary, it seems that HAV infection is not highly endemic at least in some urban areas of Iran. On the basis of this epidemiologic data, post exposure prophylaxis would be necessary for children and young adults, and hepatitis A vaccination strategy should be revised.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117123     DOI: 10.1023/b:ejep.0000020345.37091.cd

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  27 in total

Review 1.  Hepatitis A.

Authors:  R S Koff
Journal:  Lancet       Date:  1998-05-30       Impact factor: 79.321

2.  The changing epidemiological pattern of hepatitis A in Lisbon, Portugal.

Authors:  R T Marinho; A R Valente; F J Ramalho; M C de Moura
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-08       Impact factor: 2.566

3.  Hepatitis A shifting epidemiology in Latin America.

Authors:  J Tanaka
Journal:  Vaccine       Date:  2000-02-18       Impact factor: 3.641

4.  A ten year serological survey of hepatitis A, B and C viruses infections in Nepal.

Authors:  Y Sawayama; J Hayashi; I Ariyama; N Furusyo; T Kawasaki; M Kawasaki; K Itoh; G P Acharya; S Kashiwagi
Journal:  J Epidemiol       Date:  1999-11       Impact factor: 3.211

5.  Prevalence of antibody against hepatitis A in Sweden in relation to age and type of community.

Authors:  O Weiland; J V Berg; M Böttiger; P Lundbergh
Journal:  Scand J Infect Dis       Date:  1980

6.  The epidemiology of hepatitis A infection in Palestine: a universal vaccination programme is not yet needed.

Authors:  K Yassin; R Awad; A Tebi; A Queder; U Laaser
Journal:  Epidemiol Infect       Date:  2001-10       Impact factor: 2.451

7.  Prevalence of antibodies to hepatitis A, B, C, and E viruses in a healthy population in Leon, Nicaragua.

Authors:  O M Perez; W Morales; M Paniagua; O Strannegard
Journal:  Am J Trop Med Hyg       Date:  1996-07       Impact factor: 2.345

8.  Age-specific prevalence of hepatitis A virus antibody in Ethiopian children.

Authors:  E Tsega; E Nordenfelt; B Mengesha; B G Hansson; M Tsega; J Lindberg
Journal:  Scand J Infect Dis       Date:  1990

9.  Epidemiology of hepatitis A in Mediterranean countries.

Authors:  G Papaevangelou
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

10.  Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992.

Authors:  V A Arankalle; S A Tsarev; M S Chadha; D W Alling; S U Emerson; K Banerjee; R H Purcell
Journal:  J Infect Dis       Date:  1995-02       Impact factor: 5.226

View more
  9 in total

1.  High Prevalence of Symptomatic Hepatitis A Infection in Rural Area of Chaharmahal VA Bakhtiari Province, Iran.

Authors:  Ali Karimi; Seifollah Mortazaei; Mohammad-Taghi Moradi
Journal:  J Clin Diagn Res       Date:  2015-02-01

2.  Hepatitis A virus infection: Is it an important hazard to public health?: hazards of HAV for public health.

Authors:  Mehdi Saberifiroozi
Journal:  Hepat Mon       Date:  2011-04       Impact factor: 0.660

3.  Seroprevalence study of hepatitis A virus in Fars province, southern Iran.

Authors:  Seyed Alireza Taghavi; Mohammad Kazem Hosseini Asl; Mozaffar Talebzadeh; Ahad Eshraghian
Journal:  Hepat Mon       Date:  2011-04-01       Impact factor: 0.660

4.  Age-specific seroprevalence of anti-hepatitis a antibody among 1-30 years old population of savadkuh, mazandaran, iran with literature review.

Authors:  Mohammed Jafar Saffar; Omid Abedian; Abolghasem Ajami; Farshideh Abedian; Araz Mohammad Mirabi; Ali-Reza Khalilian; Hana Saffar
Journal:  Hepat Mon       Date:  2012-05-30       Impact factor: 0.660

5.  Seropositivity of Hepatitis A in Children Aged 7-14 Years in Diyarbakir Province Center.

Authors:  Ayfer Gözü Pirinççioğlu; Salih Adıgüzel; Tuncer Özekinci
Journal:  Med Sci Monit       Date:  2018-02-15

6.  Seroprevalence of anti-hepatitis a antibody among 1 - 15 year old children in kashan-iran.

Authors:  Abbas Taghavi Ardakani; Babak Soltani; Mojtaba Sehat; Somayeh Namjoo; Mostafa Haji Rezaei
Journal:  Hepat Mon       Date:  2013-05-27       Impact factor: 0.660

7.  Prevention of hepatitis a virus infection, need to vaccinate or not?

Authors:  Pegah Karimi Elizee; Seyed-Moayed Alavian
Journal:  Int J Prev Med       Date:  2013-08

8.  Hepatitis a virus: is vaccination necessary in middle East?

Authors:  Mehdi Saberifiroozi
Journal:  Middle East J Dig Dis       Date:  2013-07

9.  Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran.

Authors:  Khashayar Hesamizadeh; Heidar Sharafi; Hossein Keyvani; Seyed Moayed Alavian; Azar Najafi-Tireh Shabankareh; Roghiyeh Sharifi Olyaie; Maryam Keshvari
Journal:  Hepat Mon       Date:  2016-01-23       Impact factor: 0.660

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.